ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

Second FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing deep and durable complete remission rates combined with a well-tolerated safety ...

Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific ...

Cedars-Sinai scientists have developed an experimental drug that repairs DNA and serves as a prototype for a new class of ...

Chonnam National University has once again solidified its international reputation as Korea's leading institution in "nano-regenerative medicine" ...

Airiver Medical, a clinical stage company developing technologies to help patients who suffer from certain respiratory tract conditions, received investigational device exemption (IDE) approval from ...

The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and ...

Vertex Pharmaceuticals Incorporated ( VRTX) Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:00 AM EST ...

O RLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination ...

AD is a progressive, relentless disease with Aß and tau as hallmarks. It is caused by a continuous underlying neurotoxic process driven by PF that begins before amyloid plaque accumulation and ...